Compound ID | 3630

Update compound information

JNJ-6640

Class: Small molecule antibacterial agent

Agent Type: Synthetic; Small molecule; Direct acting;
Spectrum of activity: Antimycobacterial
Mechanism of action: De novo purine synthesis inhibitor; PurF inhibitor
Target Pathogen: Active against Mycobacterium tuberculosis
Description: Synthetic compound; developed with improved potency from an early screening hit (JNJ-7310); comparable efficacy to linezolid when used in combination with bedaquiline and pretomanid in mice infected with TB; highly selective to Mycobacterium tuberculosis PurF; rapidly metabolised (high clearance) in mice
Institute where first reported: Janssen Global Public Health, LLC, Janssen Pharmaceutica NV, Antwerp, Belgium
Year first mentioned: 2025
Development status: Experimental
Chemical structure(s):
Click here for structure editor
Molecular weight: 340.36
Iso. SMILES: FC1=C(OC2=CC(C)=NN2)N=C(N3C[C@H](C4=CC=NC=C4)CC3)N=C1
InChI Key: HOKZRBANYAPIKU-CYBMUJFWSA-N
Can. SMILES: CC1=NNC(=C1)OC2=C(C=NC(=N2)N3CC[C@H](C3)C4=CC=NC=C4)F
InChI: InChI=1S/C17H17FN6O/c1-11-8-15(23-22-11)25-16-14(18)9-20-17(21-16)24-7-4-13(10-24)12-2-5-19-6-3-12/h2-3,5-6,8-9,13H,4,7,10H2,1H3,(H,22,23)/t13-/m1/s1
External links:
Structure link: https://pubchem.ncbi.nlm.nih.gov/compound/176516507
Guide to Pharmacology: JNJ-6640
Citation: https://www.nature.com/articles/s41586-025-09177-7

AntibioticDB is supported by GARDP.

If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions

The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.